Number of patients who experience a minimum clinically important improvement in symptoms is reported. A patient was categorized as having an improvement if the mean score of any two consecutive post-baseline Average Symptom Burden Index (ASBI) score of Lung Cancer Symptom Scale (LCSS) assessments for that patient was at least 10 points below the patient's ASBI score of LCSS at enrolment, over 6 months of treatment.

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Each item is scored on a 100-millimeter (mm) Visual Analogue Scale (VAS), with score reported from 0 to 100, with 0 representing the best score. ASBI score was calculated by the mean of the 6 major lung cancer symptoms (loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis). For a given assessment, if any of the six symptom-specific questions was not completed, the ASBI score was not calculated.

All eligible subjects that have received at least one dose of afatinib in the study and who had two consecutive post-baseline Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index (ASBI) assessments over the 6-month treatment period.

Patient-rated ASBI score of LCSS at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study) is reported.

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Each item was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score. ASBI score was calculated by the mean of the 6 major lung cancer symptoms (loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis). For a given assessment, if any of the six symptom-specific questions had not been completed, the ASBI score was not calculated.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated total LCSS score -defined as the average of the aggregate score of all 9 items that comprise the LCSS- at enrolment and at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Each item was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score. ASBI score was calculated by the mean of the 6 major lung cancer symptoms (loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis). For a given assessment, if any of the six symptom-specific questions had not been completed, the ASBI score was not calculated.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Loss of appetite at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Loss of appetite was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Fatigue at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Fatigue was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Cough at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Cough was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Dyspnoea at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Dyspnoea was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Haemoptysis at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Haemoptysis was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Pain at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Pain was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Overall symptomatic distress at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Overall symptomatic distress was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score. ASBI score was calculated by the mean of the 6 major lung cancer symptoms (loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis). For a given assessment, if any of the six symptom-specific questions had not been completed, the ASBI score was not calculated.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Interference with normal activity at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Interference with normal activity was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score. ASBI score was calculated by the mean of the 6 major lung cancer symptoms (loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis). For a given assessment, if any of the six symptom-specific questions had not been completed, the ASBI score was not calculated.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Patient-rated LCSS individual item scores: Global Quality of Life (QoL) at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The patient-rated scale consists of six symptom-specific questions that address loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis. Global Quality of Life (QoL) was scored on a 100-mm Visual Analogue Scale (VAS), with scores reported from 0 to 100 with 0 representing the best score. ASBI score was calculated by the mean of the 6 major lung cancer symptoms (loss of appetite, fatigue, cough, dyspnoea, pain and haemoptysis). For a given assessment, if any of the six symptom-specific questions had not been completed, the ASBI score was not calculated.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of patients with reported problems for the EQ-5D-3L utility index score dimension: Mobility.

The EQ-5D-3L descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1="no problems"; 2="some problems"; 3= "extreme problems". Reported are the percentage of patients with problem, consisting of both level 2 ("some problems") and level 3 ("extreme problems") with the remaining subjects having reported level 1 ("no problems").

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of patients with reported problems for the EQ-5D-3L utility index score dimension: Self-care.

The EQ-5D-3L descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1="no problems"; 2="some problems"; 3= "extreme problems". Reported are the percentage of patients with problem, consisting of both level 2 ("some problems") and level 3 ("extreme problems") with the remaining subjects having reported level 1 ("no problems").

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of patients with reported problems for the EQ-5D-3L utility index score dimension: Usual activities.

The EQ-5D-3L descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1="no problems"; 2="some problems"; 3= "extreme problems". Reported are the percentage of patients with problem, consisting of both level 2 ("some problems") and level 3 ("extreme problems") with the remaining subjects having reported level 1 ("no problems").

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of patients with reported problems for the EQ-5D-3L utility index score dimension: Pain/discomfort.

The EQ-5D-3L descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1="no problems"; 2="some problems"; 3= "extreme problems". Reported are the percentage of patients with problem, consisting of both level 2 ("some problems") and level 3 ("extreme problems") with the remaining subjects having reported level 1 ("no problems").

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of patients with reported problems for the EQ-5D-3L utility index score dimension: Anxiety/depression.

The EQ-5D-3L descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1="no problems"; 2="some problems"; 3= "extreme problems". Reported are the percentage of patients with problem, consisting of both level 2 ("some problems") and level 3 ("extreme problems") with the remaining subjects having reported level 1 ("no problems").

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

EQ-VAS score at enrolment and at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study).

The EQ-VAS is a visual analogue scale (VAS) that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of participants with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0 at baseline and at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study). ECOG has 6 grades (0-5, where 0 is the best possible score and 5 the worst):

0 = Fully active, able to carry on all pre-disease performance without restriction.

1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
2. = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.
3. = Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
4. = Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
5. = Dead.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of participants with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 1 at baseline and at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study). ECOG has 6 grades (0-5, where 0 is the best possible score and 5 the worst):

0 = Fully active, able to carry on all pre-disease performance without restriction.

1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
2. = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.
3. = Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
4. = Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
5. = Dead.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of participants with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 2 at baseline and at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study). ECOG has 6 grades (0-5, where 0 is the best possible score and 5 the worst):

0 = Fully active, able to carry on all pre-disease performance without restriction.

1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
2. = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.
3. = Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
4. = Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
5. = Dead.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of participants with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 3 at baseline and at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study). ECOG has 6 grades (0-5, where 0 is the best possible score and 5 the worst):

0 = Fully active, able to carry on all pre-disease performance without restriction.

1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
2. = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.
3. = Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
4. = Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
5. = Dead.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Percentage of participants with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 4 at baseline and at the post-baseline predefined timepoints (i.e., every 2 months (± 3 weeks) during the first 12 months of therapy and every 6 months (±3 weeks) thereafter until the end of patient's participation in the study). ECOG has 6 grades (0-5, where 0 is the best possible score and 5 the worst):

0 = Fully active, able to carry on all pre-disease performance without restriction.

1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
2. = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.
3. = Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
4. = Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
5. = Dead.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who provided data to this endpoint.

Ratio of afatinib tablets actually taken to doses prescribed over the study participation period. Ratio = doses taken / doses prescribed.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who were evaluable for treatment adherence.

Number of patients with a reason for missing afatinib tablets. One participant can have multiple missing doses for multiple reasons.

All subjects who were evaluable for treatment adherence and had missed doses. One participant can have multiple missing doses for multiple reasons.

Number of patients with a reason for discontinuation of Afatinib throughout the study observation period.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who discontinued treatment.

Number of patients with a reason for treatment interruptions throughout the study observation period. One participant can have multiple interruptions for multiple reasons.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who had treatment interruptions. One participant can have multiple interruptions for multiple reasons.

Number of participants with Afatinib interruptions or dose modifications (i.e., a dose increase or decrease).

All eligible subjects that have received at least one dose of Afatinib in the study.

Number of patients with a reason for dose reduction throughout the study observation period.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who had a dose reduction.

Number of patients with a reason for dose increase throughout the study observation period.

All eligible subjects who have been enrolled into the study regardless of whether or not they have finally completed their projected participation in the study and who had a dose increase.